Addex Therapeutics Ltd (ADXN)

NCM – Real Time Price. Currency in USD

6.70

-0.16 (-2.33%)

At close: May 12, 2026, 4:00 PM EDT

30.04.2026

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders Cash position of CHF 1.6 million at December 31, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.

29.04.2026

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.

21.04.2026

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model.

07.01.2026

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.

11.12.2025

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C.

04.12.2025

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

04.12.2025

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.

Videos

No Data

There is no data to display

Press releases

30.04.2026

Addex Therapeutics Ltd (ADXN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Addex Therapeutics Ltd (ADXN)

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Search stocks

Addex Therapeutics Ltd (ADXN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Addex Therapeutics Ltd (ADXN)

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia